Dr Matthew Lunning

Dr. Matthew Lunning, a hematologist-oncologist from the Fred and Pamela Buffett Cancer Center, shares vital insights on managing CAR T-cell therapy toxicities. He discusses the evolution of CRS and ICANS management and highlights the importance of long-term studies and referral timing. Lunning compares CAR T products, emphasizing the advantages of lisocabtagene for older patients. He also shares intriguing case studies that reveal the nuances of treatment outcomes, particularly in managing neurotoxic effects and patient quality of life.

Dr. Matthew Lunning is a hematologist specializing in CAR T-cell therapy and bispecific antibodies, while Dr. Sonali M. Smith focuses on lymphoma research and treatment innovations. They discuss the complexities of logistic challenges and early referral strategies for CAR T therapies in high-risk diffuse large B-cell lymphoma (DLBCL). The conversation also highlights the effectiveness of novel agents like epcoritamab and the importance of managing toxicities. They delve into evolving treatment protocols, including the sequence of using bispecifics before CAR T for optimal outcomes.

Dr. Matthew Lunning, an expert in B-cell lymphomas, discusses CAR T-cell therapy's logistics and its efficacy against standard care in high-risk diffuse large B-cell lymphoma (DLBCL). Alongside him, Dr. Sonali M. Smith, a senior lymphoma investigator, shares insights on frontline and relapsed treatments for DLBCL and follicular lymphoma. They explore the potential of bispecific antibodies, comparing their effectiveness, patient suitability, and safety in various scenarios. Their conversation reveals the evolving strategies and personalized approaches in lymphoma treatment.